Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s446, 2024. DOI: 10.25251/skin.8.supp.446. Disponível em: https://skin.dermsquared.com/skin/article/view/3083. Acesso em: 19 may. 2025.